Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient

Journal of Analytical Toxicology

Volumn 35, Issue 8, 2011, Pages 558-565

  Lankheet, Nienke A G ^a   Blank, Christian U ^b   Mallo, Henk ^b   Adriaansz, Sandra ^b   Rosing, Hilde ^a   Schellens, Jan H M ^b,c   Huitema, Alwin D R ^a   Beijnen, Jos H ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; N DESETHYLSUNITINIB; SUNITINIB; UNCLASSIFIED DRUG;

ACCURACY; AGED; ARTICLE; CASE REPORT; DEVICE; DRUG DETERMINATION; FEMALE; HAND FOOT SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; SENSITIVITY AND SPECIFICITY; SWEAT; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CALIBRATION; CARCINOMA, RENAL CELL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEALKYLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIMIT OF DETECTION; PROTEIN KINASE INHIBITORS; PYRROLES; REPRODUCIBILITY OF RESULTS; SWEAT; TANDEM MASS SPECTROMETRY;

EID: 82855182125     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/anatox/35.8.558     Document Type: Article

References (24)

1. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, J. Verweij, G. McArthur, I.R. Judson, M.C. Heinrich, J.A. Morgan, J. Desai, C.D. Fletcher, S. George, C.L. Bello, X. Huang, C.M. Baum, and P.G. Casali. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338 (2006).
2. R.J. Motzer, M.D. Michaelson, B.G. Redman, G.R. Hudes, G. Wilding, R.A. Figlin, M.S. Ginsberg, S.T. Kim, C.M. Baum, S.E. DePrimo, J.Z. Li, C.L. Bello, C.P. Theuer, D.J. George, and B.I. Rini. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24: 16-24 (2006).
3. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol. 66: 357-371 (2010).
4. T.J. Abrams, L.J. Murray, E. Pesenti, V.W. Holway, T. Colombo, L.B. Lee, J.M. Cherrington, and N.K. Pryer. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2: 1011-1021 (2003).
5. T.J. Abrams, L.B. Lee, L.J. Murray, N.K. Pryer, and J.M. Cherrington. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2: 471-478 (2003).
6. S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, J.P. Armand, P. Scigalla, and E. Raymond. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24: 25-35 (2006).
7. D.B. Mendel, A.D. Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.O. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J.M. Cherrington. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9: 327-337 (2003).
8. L.J. Murray, T.J. Abrams, K.R. Long, T.J. Ngai, L.M. Olson, W. Hong, P.K. Keast, J.A. Brassard, A.M. O'Farrell, J.M. Cherrington, and N.K. Pryer. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20: 757-766 (2003).
9. S.E. Rosenbaum, S. Wu, M.A. Newman, D.P. West, T. Kuzel, and M.E. Lacouture. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support. Care Cancer 16: 557-566 (2008).
10. D. Chu, M.E. Lacouture, E. Weiner, and S. Wu. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a metaanalysis. Clin. Genitourin. Cancer 7: 11-19 (2009).
11. M.E. Lacouture, S. Wu, C. Robert, M.B. Atkins, H.H. Kong, J. Guitart, C. Garbe, A. Hauschild, I. Puzanov, D.T. Alexandrescu, R.T. Anderson, L. Wood, and J.P. Dutcher. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13: 1001-1011 (2008).
12. M.E. Lacouture, L.M. Reilly, P. Gerami, and J. Guitart. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann. Oncol. 19: 1955-1961 (2008).
13. U. Jacobi, E. Waibler, P. Schulze, J. Sehouli, G. Oskay-Ozcelik, T. Schmook, W. Sterry, and J. Lademann. Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann. Oncol. 16: 1210-1211 (2005).
14. A.D. Lipworth, C. Robert, and A.X. Zhu. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77: 257-271 (2009).
15. L. Rivier. Techniques for analytical testing of unconventional samples. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 14(1): 147-165 (2000).
16. U.S. Food and Drug Administration: Centre for Drug Evaluation an Research. Guidance for Industry: Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed January 2011).
17. C.T. Viswanathan, S. Bansal, B. Booth, A.J. DeStefano, M.J. Rose, J. Sailstad, V.P. Shah, J.P. Skelly, P.G. Swann, and R. Weiner. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24: 1962-1973 (2007).
18. M. Hartley and D. Crook. PharmChek Drugs of Abuse Sweat Patch (product information), 2010.
19. E. Marchei, M. Farrè, M. Pellegrini, S. Rossi, O. García-Algar, O. Vall, and S. Pichini. Liquid chromatography-electrospray ionization mass spectrometry determination of methylphenidate and ritalinic acid in conventional and non-conventional biological matrices. J. Pharm. Biomed. Anal. 49: 434-439 (2009).
20. S. Schneider, Z. Ait-m-bark, C. Schummer, P. Lemmer, M. Yegles, B. Appenzeller, and R. Wennig. Determination of fentanyl in sweat and hair of a patient using transdermal patches. J. Anal. Toxicol. 32: 260-264 (2008).
21. A. Haouala, B. Zanolari, B. Rochat, M. Montemurro, K. Zaman, M.A. Duchosal, H.B. Ris, S. Leyvraz, N. Widmer, and L.A. Decosterd. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 1982-1996 (2009).
22. A. Sistla and N. Shenoy. Reversible Z-E isomerism and pharmaceutical implications for SU5416. Drug Dev. Ind. Pharm. 31: 1001-1007 (2005).
23. R.W. Sparidans, D. Iusuf, A.H. Schinkel, J.H. Schellens, and J.H. Beijnen. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877: 4090-4096 (2009).
24. C.D. Britten, F. Kabbinavar, J.R. Hecht, C.L. Bello, J. Li, C. Baum, and D. Slamon. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. 61: 515-524 (2008).